English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

HMP’s Positive fruquintinib POC Study Triggers Payments from Lilly

May. 13, 2015

Hutchison Medipharma announced on May 13, 2015 that it is set to receive a total of US$18 million in payments from Eli Lilly and Company (Lilly).  The payments have been triggered by the positive results of the first proof-of-concept (POC) study for fruquintinib in the treatment of patients with metastatic colorectal cancer (mCRC) in China.  Fruquintinib, a novel selective inhibitor of the Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinases, was discovered by HMP.